Addition of low-dose rosiglitazone to sulphonylurea therapy improves glycaemic control in Type 2 diabetic patients

Diabetic Medicine

Volumn 17, Issue 1, 2000, Pages 40-47

  Wolffenbuttel, Bruce H R ^a   Gomis, R ^b   Squatrito, S ^c   Jones, N P ^d   Patwardhan, R N ^d  

^a MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^b HOSPITAL CLÍNIC   (Spain)

^c GARIBALDI HOSPITAL   (Italy)

^d GLAXOSMITHKLINE   (United Kingdom)

Author keywords

Glycaemic control; Rosiglitazone; Sulphonylurea; Thiazolidinedione; Type 2 diabetes mellitus

Indexed keywords

GLIBENCLAMIDE; GLICLAZIDE; GLIMEPIRIDE; GLIPIZIDE; ORAL ANTIDIABETIC AGENT; PLACEBO; ROSIGLITAZONE; SULFONYLUREA DERIVATIVE; THIAZOLIDINE DERIVATIVE;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES CONTROL; DIABETES MELLITUS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG SAFETY; FEMALE; GLUCOSE BLOOD LEVEL; HEADACHE; HUMAN; HYPOGLYCEMIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

ADULT; AGED; BLOOD GLUCOSE; C-PEPTIDE; CHOLESTEROL; CHOLESTEROL, HDL; CHOLESTEROL, LDL; DIABETES MELLITUS, TYPE 2; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; EUROPE; FEMALE; FRUCTOSAMINE; GLICLAZIDE; GLIPIZIDE; GLYBURIDE; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; MALE; MIDDLE AGED; SAFETY; THIAZOLES; THIAZOLIDINEDIONES; TRIGLYCERIDES;

EID: 0033975057     PISSN: 07423071     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1464-5491.2000.00224.x     Document Type: Article

References (32)

1. 1 DeFronzo RA, Bonadonna RC, Ferrannini E. Pathogenesis of NIDDM. Diabetes Care 1992; 15: 318-368.
2. 2 Reaven GM. Role of insulin resistance in human disease (syndrome X): an expanded definition. Annu Rev Med 1993; 44: 121-131.
3. 3 Saltiel AR, Olefsky JM. Thiazolidinediones in the treatment of insulin resistance and type II diabetes. Diabetes 1996; 45: 1661-1669.
4. 4 Heine RJ. Role of sulfonylureas in non-insulin-dependent diabetes mellitus: part II - 'The cons'. Horm Metab Res 1996; 28: 522-526.
5. 5 Whitcomb RW, Saltiel AR. Thiazolidinediones. Exp Opin Invest Drugs 1995; 4: 1299-1309.
6. 6 Imura H. A novel antidiabetic drug, troglitazone - reason for hope and concern. N Engl J Med 1998; 338: 908-909.
7. 7 Smith S, Lister C, Hughes M, Buckingham R. The PPARγ agonist, BRL 49653, prevents onset of hyperglycemia and proteinuria in ZDF rats. Diabetes 1997; 46: 150A.
8. 8 Smith S, Boam D, Bretherton-Watt D, Cawthorne MA, Moore G, Loughborough S et al. Rosiglitazone increases pancreatic islet area, density and insulin content, but not insulin gene expression. Diabetes 1998; 47: A18.
9. 9 Buckingham R, Toseland N, Hughes M, Lister C, Smith S. The PPARγ agonist, BRL 49653, prevents degenerative changes in pancreatic islet β-cells in ZDF rats. Diabetes 1997; 46: 165A.
10. 10 Miller E, Patel J, Reichek N, Granett J. BRL 49653 (a thiazolidinedione) is well tolerated and has no effect on LV mass following 12 weeks treatment in NIDDM patients. Diabetes 1997; 46: 96A.
11. 11 Patel J, Anderson RJ, Rappaport EB. Rosiglitazone monotherapy improves glycaemic control in patients with type 2 diabetes: a twelve-week, randomized, placebo-controlled study. Diab Obesity Metabol 1999; 1: 165-172.
12. 12 Hosokawa YA, Leahy JL. Parallel reduction of pancreas insulin content and insulin secretion in 48-h tolbutamide-infused normoglycemic rats. Diabetes 1997; 46: 808-813.
13. 13 Groop LC. Sulfonylureas in NIDDM. Diabetes Care 1992; 15: 737-754.
14. 14 Turner RC, Cull CA, Frighi V, Holman RR. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus. Progressive requirement for multiple therapies (UKPDS 49). JAMA 1999; 281: 2005-2012.
15. 15 National Diabetes Data Group. Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance. Diabetes 1979; 28: 1039-1057.
16. 16 Allauzen S, Joly S, Granier C, Molina F, Bouix O, Par B et al. Immunoanaiysis of 3 human insulin reveals antigenicity of some evolutionarily conserved residues. Molec Immunol 1995; 32: 27-36.
17. 17 Allauzen S, Mani JC, Granier C, Pau B, Bouanani M. Epitope mapping and binding analysis of insulin monoclonal antibodies using a biosensor approach. J Immunol Meth 1995; 183: 27-32.
18. 18 Friedewald WT, Levy RI, Fredrickson DS. Estimation of the low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972; 18: 499-502.
19. 19 Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and β cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28: 412-419.
20. 20 Buysschaert M, Bobbioni E, Starkie M, Frith L. Troglitazone in combination with sulphonylurea improves glycaemic control in Type 2 diabetic patients inadequately controlled by sulphonylurea therapy alone. Troglitazone Study Group. Diabet Med 1999; 16: 147-153.
21. 21 Kinosian B, Click H, Garland G. Cholesterol and coronary heart disease: predicting risks by levels and ratios. Ann Intern Med 1994; 121: 611-647.
22. 22 Fagot-Campagna A, Balkau B, Simon D, Warnet JM, Claude JR, Ducimetiere P et al. High free fatty acid concentration: an independent risk factor for hypertension in the Paris Prospective Study. Int J Epidemiol 1998; 27: 808-813.
23. 23 Paolisso G, Howard BV. Role of non-esterified fatty acids in the pathogenesis of Type 2 diabetes mellitus. Diabet Med 1998; 15: 360-366.
24. 24 Austin MA, Mykkanen L, Kuusisto J, Edwards KL, Nelson C, Haffner SM et al. Prospective study of small LDLs as a risk factor for non-insulin dependent diabetes mellitus in elderly men and women. Circulation 1995; 92: 1770-1778.
25. 25 Austin MA, Breslow JL, Hennekens CH, Buring JE, Willett WC, Krauss RM. Low-density lipoprotein subclass patterns and risk of myocardial infarction. JAMA 1988; 260: 1917-21.
26. 26 Krauss RM. Heterogeneity of plasma low-density lipoproteins and atherosclerosis risk. Curr Opin Lipidol 1994; 5: 339-349.
27. 27 Day C. Thiazolidinediones: a new class of antidiabetic drugs. Diabet Med 1999; 16: 179-192.
28. 28 Dogterom P, Jonkman JHG, Vallance SE. Rosiglitazone: no effect on erythropoiesis or premature red cell destruction. Diabetes 1999; 48: A98.
29. 29 Perry IJ, Wannamethee SG, Shaper AG. Prospective study of serum gamma-glutamyltransferase and risk of NIDDM. Diabetes Care 1998; 21: 732-737.
30. 30 Horton ES, Whitehouse F, Ghazzi M, Venable TC, Whitcomb RW. Troglitazone in combination with sulfonylurea restores glycemic control in patients with type 2 diabetes. Diabetes Care 1998; 21: 1462-1469.
31. 31 Raskin P, Rappaport EB. Rosiglitazone improves fasting and post-prandial plasma glucose in type 2 diabetes. Diabetes 1999; 48: A95.
32. 32 Fonseca V, Biswas N, Salzman A. Once-daily rosiglitazone (RSG) in combination with metformin (MET) effectively reduces hyperglycemia in patients with type 2 diabetes. Diabetes 1999; 48: A100.